Search
for
Sort by
Research 30 of 1000+
- Dermatologic Adverse Events from Cancer Treatments
- Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database
- “Nail loss after teriflunomide treatment: A new potential adverse event”
- Cutaneous Adverse Events in Patients with Chronic Hepatitis C during Treatment with Directly Acting Antiviral Agents: A cohort study
- Response to “The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System”
- Patient-reported treatment outcomes and safety of direct-to-consumer teledermatology for finasteride treatment in male androgenetic alopecia: A cross-sectional study
- Systemic treatments for alopecia areata: A systematic review
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Cutaneous toxicities of new treatments for melanoma
- Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
- Adverse events related to platelet-rich plasma therapy and future issues to be resolved
- Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
- [Translated article] Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review
- Survey on adverse events associated with drug therapy for breast cancer patients
- Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
- Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
- Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
- Reporting on Adverse Clinical Events
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies
- Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico
- Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
- Topical Eflornithine
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- Reporting on Adverse Clinical Events
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- Patient‐reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data
- INDIVIDUAL ARTICLE: USCOM V: A Practical Algorithm for the Prevention and Treatment of Cutaneous Side Effects of Hormonal Cancer Therapy
- Management of Serious Adverse Events Following Deoxycholic Acid Injection for Submental and Jowl Fat Reduction: A Systematic Review and Management Recommendations